China National MedicinesSHSE:600511 +1.62%86 Days Payable is 89.71 as of Mar. 2026, which is 8% above its 10-year median of 83.33. GuruFocus rates SHSE:600511 with a GF Score™ of 86/100 and a GF Value™ of ¥32.74 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 115 Medical Distribution companies, China National Medicines ranks better than 56.52% on this metric.
The historical rank and industry rank for China National Medicines's Days Payable or its related term are showing as below:
SHSE:600511'
s Days Payable Range Over the Past 10 Years
Min: 55.13 Med: 83.33 Max: 92.62
Current: 88.89
During the past 13 years, China National Medicines's highest Days Payable was 92.62. The lowest was 55.13. And the median was 83.33.
SHSE:600511's Days Payable is ranked better than 56.52% of 115
companies
in the Medical Distribution industry
Industry Median: 79.81
vs SHSE:600511: 88.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600511 vs MCK, CAH, COR: Days Payable Comparison
For the Medical Distribution subindustry, China National Medicines's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Medicines Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Medicines's Days Payable distribution charts can be found below:
* The bar in red indicates where China National Medicines's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
China National Medicines's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Medicines (SHSE:600511) has a Days Payable of 89.71 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China National Medicines and its competitors. This is near median its historical median of 83.33. Over the past decade, China National Medicines' Days Payable has ranged from 55.13 to 92.62. According to the industry distribution chart, China National Medicines ranks #50 out of 115 companies in the Medical Distribution industry, placing it in the top 43.5%.
Is China National Medicines' Days Payable too high?
China National Medicines' current Days Payable of 89.71 is near median its 10-year median of 83.33. Over the past 10 years, this metric has ranged from a low of 55.13 to a high of 92.62. The Medical Distribution industry median Days Payable is 79.81. China National Medicines' value of 89.71 is 12.4% above this industry median. Based on the distribution chart, China National Medicines ranks #50 out of 115 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, China National Medicines has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, China National Medicines ranks #50 out of 115 companies for Days Payable. This puts China National Medicines in the upper half of its industry. The industry median Days Payable is 79.81. China National Medicines' value of 89.71 is 12.4% above this benchmark. Historically, China National Medicines' own Days Payable has ranged from 55.13 to 92.62 over the past decade. While the company's 10-year median is 83.33 vs. the industry median of 79.81, China National Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.81, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Medicines's current Days Payable of 89.71 is 12.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China National Medicines and its competitors. For the Medical Distribution industry, the median Days Payable is 79.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Medicines's current Days Payable is 89.71, which is near median its own 10-year median of 83.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.74, compared to a current price of ¥26.94 — trading 17.7% below its estimated fair value. The current Days Payable is 89.71, which is near median its 10-year median of 83.33 and 12.4% above the Medical Distribution industry median of 79.81. China National Medicines' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Days Payable is 89.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.94 is trading 17.7% below its estimated GF Value™ of ¥32.74.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
Days Payable: 89.71 (near median its 10-year median of 83.33)
GF Value™: ¥32.74 vs. price of ¥26.94 (17.7% below fair value)
Industry Position: 12.4% above the Medical Distribution median (#50 of 115)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
86GF Score
Get the complete analysis for SHSE:600511
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
